KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Expenditures (2018 - 2025)

Castle Biosciences' Capital Expenditures history spans 7 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 538.92% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $11.3 million, changed N/A, while the annual FY2025 figure was $11.3 million, N/A changed from the prior year.
  • Capital Expenditures for Q4 2025 was $6.9 million at Castle Biosciences, up from -$2.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $12.7 million in Q4 2023 and bottomed at -$12.8 million in Q3 2024.
  • The 5-year median for Capital Expenditures is $2.5 million (2022), against an average of $1.7 million.
  • The largest YoY upside for Capital Expenditures was 10331.25% in 2023 against a maximum downside of 857.25% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $3.3 million in 2021, then soared by 36.68% to $4.5 million in 2022, then soared by 182.58% to $12.7 million in 2023, then crashed by 112.34% to -$1.6 million in 2024, then soared by 538.92% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Capital Expenditures are $6.9 million (Q4 2025), -$2.4 million (Q3 2025), and $3.6 million (Q2 2025).